The combination of a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) and endocrine therapy (ET) has become the new standard of care for patients with hormone receptor–positive, human epidermal growth factor receptor-2–negative (HR + /HER2 −) advanced breast cancer (ABC) [1]. The gene discussed is CDK4; the disease is breast cancer.